{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:27:49Z","timestamp":1777120069190,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/maj.0b013e3182514093","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T23:45:46Z","timestamp":1335397546000},"page":"371-374","source":"Crossref","is-referenced-by-count":45,"title":["Economic Considerations of the Treatment of Ankylosing Spondylitis"],"prefix":"10.1016","volume":"343","author":[{"given":"John D.","family":"Reveille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ximenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182514093_bb0005","unstructured":"OECD. OECD Health Data 2008, \u201cJune 2008.\u201d Available at: www. oecd.org\/dataoecd\/42\/57\/36945724.pdf. Accessed July 15, 2011."},{"key":"10.1097\/MAJ.0b013e3182514093_bb0010","unstructured":"The Commonwealth Fund. 2008 Commonwealth Fund International Health Policy Survey of Sicker Adults. Available at: www.common wealthfund.org\/.\/Surveys\/2008\/2008-Commonwealth-Fund-International-Health-Policy-Survey-of-Sicker-Adults.aspx. Accessed July 15, 2011."},{"key":"10.1097\/MAJ.0b013e3182514093_bb0015","unstructured":"3. U.S. Census Bureau Current Population Survey 2008 and 2009 Annual Social and Economic Supplements. Available at: http:\/\/www.census.gov\/prod\/2009pubs\/p60-236.pdf. Accessed July 15, 2011."},{"key":"10.1097\/MAJ.0b013e3182514093_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#","article-title":"Functional disability predicts total costs in patients with ankylosing spondylitis","volume":"46","author":"Ward","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/ard.2009.116764","article-title":"Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost","volume":"69","author":"Boonen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0030","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.62.8.732","article-title":"Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries","volume":"62","author":"Boonen","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0035","first-page":"S118","article-title":"Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Franke","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/rheumatology\/kem296","article-title":"The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit","volume":"47","author":"Ara","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","article-title":"The burden of ankylosing spondylitis in Spain","volume":"11","author":"Kobelt","year":"2008","journal-title":"Value Health"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0050","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3899\/jrheum.100099","article-title":"Cost of illness from the public payers\u2019 perspective in patients with ankylosing spondylitis in rheumatological care","volume":"37","author":"Str\u00f6mbeck","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0055","first-page":"225","article-title":"Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient\u2019s perspective","volume":"144","author":"Mould-Quevedo","year":"2008","journal-title":"Gac Med Mex"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0060","first-page":"490","article-title":"Resource utilisation and cost of ankylosing spondylitis in Brazil","volume":"28","author":"Torres","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2009.11.007","article-title":"Socioeconomic impact of ankylosing spondylitis in Tunisia","volume":"77","author":"Younes","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0070","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/ken287","article-title":"Costs and quality of life of patients with ankylosing spondylitis in Hong Kong","volume":"47","author":"Zhu","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0075","first-page":"905","article-title":"Assessment of SpondyloArthritis International Society","volume":"70","author":"van der Heijde","year":"2011","journal-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0080","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keq222","article-title":"Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany","volume":"49","author":"Neilson","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009740701607224","article-title":"The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data","volume":"37","author":"Kobelt","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.2004.032565","article-title":"Markov model into the cost-utility over 5 years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis","volume":"65","author":"Boonen","year":"2006","journal-title":"Arthritis Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.090242","article-title":"Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity in patients with ankylosing spondylitis","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0105","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2009.121327","article-title":"Double-blind placebocontrolled trial of etanercept in the prevention of work disability in ankylosing spondylitis","volume":"69","author":"Barkham","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/ard.2008.103887","article-title":"Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial","volume":"69","author":"Fautrel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0115","first-page":"513","article-title":"Low dose of infliximab is inadequate in most patients with spondylarthropathies","volume":"23","author":"Sidiropoulos","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0120","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kel156","article-title":"Low-dose infliximab treatment for ankylosing spondylitis\u2014clinically- and cost-effective","volume":"45","author":"Jois","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0125","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A doubleblind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jbspin.2010.04.017","article-title":"A 3 mg\/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs","volume":"78","author":"Tenga","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25 mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0145","doi-asserted-by":"crossref","unstructured":"Moghimi J, Sheikhvatan M, Semnani V. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series [published online ahead of print May 8, 2011]. Rheumatol Int doi: 10.1007\/s00296\u2013011\u20131920\u20130.","DOI":"10.1007\/s00296-011-1920-0"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0155","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0160","first-page":"1862","article-title":"Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients","volume":"28","author":"Sweeney","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/kep174","article-title":"Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery","volume":"49","author":"Vander Cryssen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2106\/00004623-199708000-00010","article-title":"Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis","volume":"79","author":"Sochart","year":"1997","journal-title":"J Bone Joint Surg Am"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1054\/arth.2002.32170","article-title":"Total hip arthroplasty in ankylosing spondylitis: an analysis of 181 hips","volume":"17","author":"Joshi","year":"2002","journal-title":"J Arthroplasty"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0180","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/ard.2006.061283","article-title":"Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis","volume":"66","author":"Verstrappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002822.pub3","article-title":"Physiotherapy interventions for ankylosing spondylitis","volume":"23","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0190","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3899\/jrheum.100987","article-title":"Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"38","author":"Masiero","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0195","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1001\/archinte.160.19.2969","article-title":"Exercise and changes in health status in patients with ankylosing spondylitis","volume":"160","author":"Uhrin","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0200","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ncprheum0297","article-title":"A review of work participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis","volume":"2","author":"Boonen","year":"2006","journal-title":"Nat Clin Prac Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0205","first-page":"315","article-title":"Risk factors for work disability in patients with ankylosing spondylitis","volume":"28","author":"Ward","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182514093_bb0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.23523","article-title":"Impact of ankylosing spondylitis on work and family life: comparisons with the U.S. population","volume":"59","author":"Ward","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T23:17:54Z","timestamp":1561677474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915309678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0002962915309678"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182514093","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}